BPC57 is a 15-amino acid peptide derived from a larger protein called BPC, which was discovered by a group in Croatia in the 1990s, and is not naturally produced by the human body, but rather is a fragment of a larger protein that can be isolated and studied for its potential therapeutic effects 10m0s
They are involved in protein synthesis, muscle growth and hormone regulation
Risk Factors for Adverse Reactions Some individuals may be at higher risk for side effects, and therefore, we recommend that you speak to a medical professional if you have any of the following: Pre-existing liver or kidney conditions Autoimmune disorders Hormone-sensitive conditions History of allergic reactions to peptides Long-Term Safety Considerations Its important to note several key facts about long-term safety: No human clinical trials have assessed long-term safety beyond several months Carcinogenicity (cancer-causing potential) has not been thoroughly studied The potential for developing antibodies against BPC 157 with prolonged use is unknown Possible tolerance development with continuous use has not been well-researched Long-term effects on hormone systems remain unclear Extent of Research on BPC 157 As it stands, BPC 157 still has some research gaps
28 days goes by faster than you think, especially when a peptide protocol is running in the background of a busy month
Although the precise mechanism remains unclear, it is hypothesized that their ototoxic effects stem from lysosomal dysfunction and cochlear cell apoptosis (Della Porta et al
Notably, FOXO4-DRI treatment did not cause significant changes in body weight or testis weight, suggesting a targeted effect [1]